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Debate: This house believes that SBRT should become the 
standard of care for T1 and small T2 NSCLC tumours  
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The current standard of care for T1 and small T2 early-stage 
non-small cell lung cancer (NSCLC) is surgical resection with 
lobectomy and nodal sampling/resection. There is 
randomized evidence that wedge resection is an inferior 
operation to lobectomy [1] but no large series randomized 
evidence of surgery versus any other curative intervention for 
early stage lung cancer. In addition, for patients over 71 
years there may be no benefit of lobectomy over limited 
resection[2]. Stereotactic body radiotherapy (SBRT) is not a 
new treatment and has been used in medically inoperable 
stage I NSCLC for 20 years[3]. Given the very high rates of 
local control ~90% at 3-5 years[4], the low rates of acute 
toxicity and little detriment to quality of life post 
treatment[5] SBRT is now a standard of care for medically 
inoperable peripherally located T1 and T2 tumours up to 5cm 
in diameter. For medically operable patients where the risks 
of surgery are low, surgery does offer a theoretical 
advantage over local ablative treatment such as SBRT. 
Optimum surgery with removal or the tumour and 
surrounding lobe may remove occult cancer cells outside the 
treated volume that may not be included in the SBRT 
treatment volume. In addition, nodal resection may convey 
an additional survival benefit and for those patients with 
occult N1/2 disease those patients could further benefit with 
the addition of adjuvant chemotherapy.  
However, the average age at the time of diagnosis of lung 
cancer is 70, often in patient’s with significant medical co-
morbidity that precludes lobectomy and reduces the chance 
of them receiving adjuvant chemotherapy[6]. Surgical 
mortality at both 30 and 90 days increases with age further 
reducing the potential benefit from lobectomy and nodal 
sampling/resection[7]. In addition, with PET/CT staging and 
minimally invasive techniques (EBUS) for pathologically 
sampling the mediastinum now routine practice, the chance 
of missing occult N1/N2 nodal disease is small being <9% in 
one series[8].  
Propensity analysis of patients receiving surgery versus SBRT 
have been performed on retrospective series with some 
reports suggesting no difference in survival between the two 
match groups and others suggesting a benefit with surgery. 
Randomized controlled trials (RCT) of surgery versus SBRT 
(STARS/ROSEL) have been attempted but have been closed 
prematurely due to poor accrual. A recent pooled analysis of 
the STARS and ROSEL studies showed no significant difference 
between SBRT and surgery, though a trend for improved 
survival with SABR but this was based on 58 patients[9].  
Given the limited data from STARS/ROSEL and conflicting 
results from propensity matched analysis there is a need for 
successful randomized trials of surgery versus SBRT to prove 
whether SBRT should be the standard of care. Hopefully, the 
open SABRtooth (UK) and STABLE-MATES (USA) trial combined 
with other planned trials of SBRT versus surgery will recruit 
and provide the answer to this key question. 
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For early-stage non-small cell lung cancer (NSCLC) surgical 
resection remains the treatment of choice providing 
excellent long-term results (1). Recently, stereotactic body 
radiotherapy (SBRT) has become an alternative treatment for 
localized NSCLC (2). SBRT has mainly been applied for 
functionally in operable patients with severe 
cardiopulmonary morbidity. Currently, there is an ongoing 
debate whether SBRT is also a valid oncological treatment for 
low-risk patients who are operable from a technical and 
functional perspective. No large randomized studies are 
available directly comparing SBRT and surgical resection with 
systematic lymph node dissection. Several trials closed 
prematurely due to poor accrual.  
From a thoracic surgical point of view several concerns 
emerge when applying SBRT to operable early-stage NSCLC: 
precise pathology is not obtained in all cases, information on 
locoregional lymph node involvement is not always available 
making it difficult to recommend adjuvant chemotherapy in 
specific cases, and rather troublesome, different criteria are 
used when comparing results of surgery and SBRT, mainly in 
relation to local recurrence (3,4). Moreover, thoracic 
surgeons are more and more dealing with “salvage surgery” 
after previous radiotherapy when no other therapeutic 
options are available (5). Technically, these resections may 
be very challenging due to technical difficulties during 
dissection of the hilar region not encountered during primary 
intervention. These procedures should be performed in 
dedicated thoracic centres with a large experience.  
Due to the lack of clear evidence, different opinions are 
expressed in present-day literature.  
In a pooled analysis of two randomised trials comparing SBRT 
with lobectomy for stage I NSCLC that closed prematurely 
due to poor accrual, the authors concluded that SBRT can be 
considered a valid treatment option for operable stage I 
NSCLC (6). However, because of small patient sample size 
and short follow-up time, they indicate that further 
randomized studies should be performed before more 
definite recommendations can be made (6).  
A different conclusion was reached in a recent propensity 
score analysis matching 41 patients who underwent video-
assisted (VATS) lobectomy with 41 patients treated with SBRT 
for stage I NSCLC (7). Significant differences were found in 
overall survival, cause-specific survival, recurrence-free 
survival, local and distant control favouring VATS lobectomy. 
Conclusion of this study was that VATS lobectomy may offer a 
significantly better long-term outcome than SBRT in 
potentially operable patients with biopsy-proven clinical 
stage I NSCLC.  
